Literature DB >> 18365140

Elevated serum levels of soluble interleukin-2 receptor in chronic eosinophilic leukemia/hypereosinophilic syndrome with FIP1L1-PDGFR alpha fusion gene.

Keisuke Kataoka1, Koji Izutsu1, Sumimasa Nagai1, Akira Hangaishi1, Toru Motokura1, Tsuyoshi Takahashi1, Mineo Kurokawa2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18365140     DOI： 10.1007/s12185-008-0064-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  6 in total

1.  Increased levels of soluble interleukin-2 receptor in non-Hodgkin's lymphomas. Relationship with clinical, histologic, and phenotypic features.

Authors:  M Chilosi; G Semenzato; F Vinante; F Menestrina; E Piazzola; V Focchiatti; R Sabbioni; R Zanotti; G Pizzolo
Journal:  Am J Clin Pathol       Date:  1989-08       Impact factor: 2.493

2.  Elevated serum levels of soluble interleukin-2 receptor: a marker of disease activity in the hypereosinophilic syndrome.

Authors:  L Prin; J Plumas; V Gruart; S Loiseau; D Aldebert; J C Ameisen; A Vermersch; P Fenaux; O Bletry; M Capron
Journal:  Blood       Date:  1991-11-15       Impact factor: 22.113

3.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

4.  Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.

Authors:  Keisuke Miyazawa; Naoki Kakazu; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

Review 5.  Diagnosis and treatment of hypereosinophilic syndromes.

Authors:  Sarah Fletcher; Barbara Bain
Journal:  Curr Opin Hematol       Date:  2007-01       Impact factor: 3.284

6.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Authors:  Jelena V Jovanovic; Joannah Score; Katherine Waghorn; Daniela Cilloni; Enrico Gottardi; Georgia Metzgeroth; Philipp Erben; Helena Popp; Christoph Walz; Andreas Hochhaus; Catherine Roche-Lestienne; Claude Preudhomme; Ellen Solomon; Jane Apperley; Michela Rondoni; Emanuela Ottaviani; Giovanni Martinelli; Finella Brito-Babapulle; Giuseppe Saglio; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter; David Grimwade
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.